Imeglimin_product_DataBase

Bioactivity	Imeglimin (EMD 387008) is an oral glucose-lowering agent. Imeglimin improves insulin sensitivity. Imeglimin also reduces reactive oxygen species (ROS) production, increases mitochondrial DNA and improves mitochondrial function[1].
Target	ROS; mitochondrial function
Invitro	Preincubation with Imeglimin (10 mM for 4 h or 100 μM for 24 h) fully prevents tert-butylhydroperoxide (tBH)-induced cell death[2]. Cell Viability Assay[2] Cell Line:
In Vivo	Imeglimin (200 mg/kg b.i.d. by oral gavage during the last 6 weeks of HFHSD feeding) significantly decreases hyperglycemia, restores normal glucose tolerance, and improves insulin sensitivity[1]. Animal Model:
Name	Imeglimin
CAS	775351-65-0
Formula	C6H13N5
Molar Mass	155.20
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Vial G, et al. Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrialfunction in liver of a high-fat, high-sucrose diet mice model. Diabetes. 2015 Jun;64(6):2254-64. [2]. Detaille D, et al. Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration. Cell Death Discov. 2016 Jan 18;2:15072.

PeptideDB